Marreiros Catarina, Viegas Carla, Guedes Anabela Malho, Silva Ana Paula, Águas Ana Catarina, Faísca Marília, Schurgers Leon, Simes Dina Costa
Centre of Marine Sciences, University of Algarve, 8005-139 Faro, Portugal.
GenoGla Diagnostics, CCMAR, Universidade do Algarve, 8005-139 Faro, Portugal.
J Clin Med. 2024 Dec 6;13(23):7429. doi: 10.3390/jcm13237429.
: Vascular calcification (VC) is a crucial risk factor for cardiovascular diseases (CVD), particularly in chronic kidney disease (CKD) populations. However, the specific relationship between VC and end-stage renal disease (ESRD) patients undergoing peritoneal dialysis (PD) remains to be fully understood. The identification of new biomarkers to improve VC diagnosis and monitoring would significantly impact cardiovascular risk management in these high-risk patients. Gla-rich protein (GRP) is a VC inhibitor and an anti-inflammatory agent and thus is a potential VC marker in CKD. Here we explored the potential role of GRP as a marker for CVD and investigated the impact of VC in 101 PD patients. : Circulating total Gla-rich protein (tGRP) was quantified in serum and in 24 h dialysate samples. VC score (VCS) was determined using the Adragão method. Serum tGRP was negatively associated with VCS, serum calcium (Ca), phosphate (P), and high-sensitivity C-reactive protein (hsCRP), while it was positively associated with magnesium (Mg). A total of 35.6% of PD patients presented with extensive calcifications (VCS ≥ 3), and the lowest tGRP serum levels were present in this group (419.4 ± 198.5 pg/mL). tGRP in the 24 h dialysate was also negatively associated with VCS and with serum Ca and P. Moreover, serum Ca, P, and VCS were identified as independent determinants of serum tGRP levels. : The association of serum tGRP with VC, mineral, and inflammation markers reinforces its potential use as a novel VC biomarker in CKD patients undergoing PD.
血管钙化(VC)是心血管疾病(CVD)的关键危险因素,在慢性肾脏病(CKD)人群中尤为如此。然而,VC与接受腹膜透析(PD)的终末期肾病(ESRD)患者之间的具体关系仍有待充分了解。识别新的生物标志物以改善VC的诊断和监测,将对这些高危患者的心血管风险管理产生重大影响。富含γ-羧基谷氨酸蛋白(GRP)是一种VC抑制剂和抗炎剂,因此是CKD中潜在的VC标志物。在此,我们探讨了GRP作为CVD标志物的潜在作用,并研究了VC对101例PD患者的影响。:对血清和24小时透析液样本中的循环总富含γ-羧基谷氨酸蛋白(tGRP)进行定量。使用阿德拉戈方法确定VC评分(VCS)。血清tGRP与VCS、血清钙(Ca)、磷(P)和高敏C反应蛋白(hsCRP)呈负相关,而与镁(Mg)呈正相关。共有35.6%的PD患者出现广泛钙化(VCS≥3),该组患者的tGRP血清水平最低(419.4±198.5 pg/mL)。24小时透析液中的tGRP也与VCS以及血清Ca和P呈负相关。此外,血清Ca、P和VCS被确定为血清tGRP水平的独立决定因素。:血清tGRP与VC、矿物质和炎症标志物之间的关联,强化了其作为接受PD的CKD患者新型VC生物标志物的潜在用途。